Status:
RECRUITING
Prediction Model for Response to Biologics and Small Molecular Agent for UC
Lead Sponsor:
Asan Medical Center
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
18-79 years
Brief Summary
This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.
Detailed Description
In this prospective observational study, patients with confirmed ulcerative colitis, who are going to receive vedolizumab, ustekinumab, or tofacitinib will be enrolled after an informed consent. In th...
Eligibility Criteria
Inclusion
- Patients with an established diagnosis of ulcerative colitis based on clinical symptoms, endoscopic features and histopathologic features
- Patients who are going to receive vedolizumab, ustekinumab, or tofacitinib treatment
Exclusion
- Not Korean ethnicity by family history
- Inflammatory Bowel Disease Unclassified
- Patients who already received colectomy due to ulcerative colitis
Key Trial Info
Start Date :
February 5 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05186623
Start Date
February 5 2022
End Date
December 31 2026
Last Update
February 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 05505